Arcturus Therapeutics Holdings Inc [ARCT] stock is trading at $19.07, up 6.30%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARCT shares have gain 12.04% over the last week, with a monthly amount glided 10.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] stock has seen the most recent analyst activity on August 12, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $70. Previously, Canaccord Genuity started tracking the stock with Buy rating on December 13, 2023, and set its price target to $90. On July 24, 2023, William Blair initiated with a Outperform rating and assigned a price target of $71 on the stock. H.C. Wainwright upgraded its rating to a Buy and increased its price target to $51 on May 11, 2023. Robert W. Baird downgraded its rating to Underperform for this stock on November 10, 2022, but kept the price target unchanged to $18. In a note dated November 03, 2022, Citigroup upgraded an Buy rating on this stock and boosted its target price from $22 to $35.
Arcturus Therapeutics Holdings Inc [ARCT] stock has fluctuated between $14.30 and $45.00 over the past year. Currently, Wall Street analysts expect the stock to reach $10.58 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $19.07 at the most recent close of the market. An investor can expect a potential drop of -44.52% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] reported sales of 145.60M for the trailing twelve months, which represents a drop of -10.52%. Gross Profit Margin for this corporation currently stands at 1.05% with Operating Profit Margin at -0.38%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.22 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.23 points at the first support level, and at 17.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.54, and for the 2nd resistance point, it is at 20.00.
Ratios To Look Out For
For context, Arcturus Therapeutics Holdings Inc’s Current Ratio is 4.76. Also, the Quick Ratio is 4.76, while the Cash Ratio stands at 3.41. Considering the valuation of this stock, the price to sales ratio is 3.73, the price to book ratio is 1.97.
Transactions by insiders
Recent insider trading involved Chivukula Pad, Chief Scientific Officer & COO, that happened on Oct 15 ’24 when 12000.0 shares were sold. Officer, Chivukula Pad completed a deal on Oct 15 ’24 to buy 12000.0 shares. Meanwhile, Chief Financial Officer SASSINE ANDY sold 50000.0 shares on Jun 12 ’24.
